Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
9 studies found for:    "Signet ring cell carcinoma"
Show Display Options
Rank Status Study
1 Active, not recruiting Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
Condition: Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
Interventions: Drug: S-1 (Tegafur/Gimeracil/Oteracil) /cisplatin (investigational arm);   Drug: Fluorouracil/cisplatin (control arm)
2 Not yet recruiting Endodrill vs. Conventional Biopsy. Evaluation of Diagnostic Capacity in Diffuse Gastric Cancer
Condition: Stomach Neoplasms
Interventions: Device: Boston Scientific Large Capacity with needle Biopsy;   Device: Endodrill 1A (BIBBInstruments, Lund, Sweden)
3 Completed Signet Ring Cell Carcinoma in Esophageal Adenocarcinoma
Conditions: Adenocarcinoma;   Esophageal Cancer
Intervention:
4 Completed Prognosis of Signet Ring Cells in Upper Digestive Neoplasms
Conditions: Signet Ring Cell Carcinoma;   Stomach Disease;   Oesophagus;   Prognostic;   Case-control Study
Intervention:
5 Recruiting Hereditary Colorectal and Associated Tumor Registry Study
Conditions: Lynch Syndrome;   FAP;   Hereditary Diffuse Gastric Cancer;   Juvenile Polyposis Syndrome;   Peutz-Jeghers Syndrome
Intervention: Other: Research Registry
6 Active, not recruiting Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Conditions: Colon Mucinous Adenocarcinoma;   Colon Signet Ring Cell Adenocarcinoma;   Rectal Mucinous Adenocarcinoma;   Rectal Signet Ring Cell Adenocarcinoma;   Recurrent Colon Carcinoma;   Recurrent Rectal Carcinoma;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
7 Terminated Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer
Conditions: Colon Mucinous Adenocarcinoma;   Colon Signet Ring Cell Adenocarcinoma;   Rectal Mucinous Adenocarcinoma;   Rectal Signet Ring Cell Adenocarcinoma;   Recurrent Colon Carcinoma;   Recurrent Rectal Carcinoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Biological: Cetuximab;   Drug: Gamma-Secretase Inhibitor RO4929097;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
8 Not yet recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Conditions: Adenoid Cystic Carcinoma;   Adnexal Carcinoma;   Apocrine Carcinoma;   Eccrine Porocarcinoma;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Non-Melanomatous Lesion;   Paget Disease;   Papillary Adenocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamous Cell Carcinoma of Unknown Primary Origin;   Stage III Skin Cancer;   Stage IV Skin Cancer;   Sweat Gland Carcinoma;   Trichilemmocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec
9 Active, not recruiting Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
Conditions: Colon Mucinous Adenocarcinoma;   Colon Signet Ring Cell Adenocarcinoma;   Lynch Syndrome;   Stage IIA Colon Cancer;   Stage IIB Colon Cancer;   Stage IIC Colon Cancer
Interventions: Biological: Bevacizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin

Study has passed its completion date and status has not been verified in more than two years.